贝林妥欧单抗巩固治疗高危Ph阴性B细胞急性淋巴细胞白血病:GRAALL-2014/B-QUEST研究
该2期子研究评估将贝林妥欧单抗整合入高危Ph阴性B-ALL成人患者的巩固与维持治疗。2018-2020年入组94例高危患者接受最多5个28天周期的贝林妥欧单抗,与90例未接受贝林妥欧单抗的历史对照进行事后分析比较。贝林妥欧单抗显著改善MRD清除、减少复发并延长生存,5年复发率23%对49%,DFS 68%对42%,OS 79%对60%。
要点
- 贝林妥欧单抗巩固治疗显著改善高危Ph阴性B-ALL的MRD清除并降低复发。
- 5年DFS和OS在贝林妥欧单抗组分别为68%和79%,优于对照组的42%和60%。
- 适合异基因造血干细胞移植的患者整体获益,但最终接受移植者未见明确额外DFS优势。
核心结论
- 贝林妥欧单抗整合入巩固和维持治疗可显著改善高危Ph阴性B-ALL成人患者的MRD清除、降低复发并延长生存。
- 研究结果支持贝林妥欧单抗的前线整合,并提示需在该背景下前瞻性评估移植策略。
研究设计与样本
- 2期GRAALL-2014/B-QUEST子研究,2015-2020年纳入489例18-59岁新诊断Ph阴性B-ALL成人,其中259例归类为高危。
- 94例高危患者于2018-2020年入组QUEST研究,接受最多5个28天周期的贝林妥欧单抗巩固和维持治疗。
- 90例在QUEST启动前治疗、未接受贝林妥欧单抗的高危患者作为事后分析对照,两组基线特征可比。
主要发现
- 贝林妥欧单抗巩固显著改善MRD清除、减少复发并延长生存。
- 5年累积复发率、DFS和OS在贝林妥欧单抗组分别为23%、68%和79%,对照组分别为49%(P = .001)、42%(P = .001)和60%(P = .03)。
- 适合异基因造血干细胞移植的患者整体获益,但最终接受移植者未见明确的额外DFS优势。
关键数值与推荐
- 高危定义:存在KMT2A-r、IKZF1缺失或诱导结束MRD ≥ 10-4。
- 贝林妥欧单抗给药:巩固和维持期间最多5个28天周期。
- 5年累积复发率:贝林妥欧单抗组23% vs 对照组49%(P = .001)。
- 5年DFS:贝林妥欧单抗组68% vs 对照组42%(P = .001)。
- 5年OS:贝林妥欧单抗组79% vs 对照组60%(P = .03)。
临床怎么用
- 对于高危Ph阴性B-ALL成人患者,可考虑在巩固和维持治疗中前线整合贝林妥欧单抗。
- 适合异基因造血干细胞移植的患者可从贝林妥欧单抗治疗中整体获益。
- 最终接受移植者未见明确额外DFS优势,移植策略需前瞻性评估。
局限性
- 对照为QUEST启动前治疗的历史患者,采用事后分析,非随机对照。
- 样本量有限,贝林妥欧单抗组94例,对照组90例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intensified chemotherapy regimens have improved outcomes in adults with Philadelphia chromosome-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL), yet relapse remains a major cause of treatment failure and death. Blinatumomab is a T-cell engager that demonstrated marked activity in relapsed and measurable residual disease-positive (MRD+) B-ALL, as well as in frontline consolidation for MRD- patients. The phase 2 GRAALL-2014/B-QUEST substudy evaluated the integration of blinatumomab into consolidation and maintenance therapy for adults with high-risk (HR) B-ALL. Between 2015 and 2020, 489 adults aged 18 to 59 years with newly diagnosed Ph- B-ALL were enrolled, and among these 259 were classified as HR (presence of KMT2A-r, IKZF1 deletion, or end-of-induction MRD ≥ 10-4). A total of 94 patients with HR were enrolled in the QUEST study (2018-2020) and received up to 5, 28-day cycles of blinatumomab during consolidation and maintenance. In addition, 90 patients with HR who were treated before QUEST activation without blinatumomab served as controls in a post hoc analysis. Baseline characteristics were comparable between groups. Blinatumomab consolidation significantly improved MRD clearance, reduced relapse, and prolonged survival. At 5 years, cumulative incidence of relapse, disease-free survival (DFS), and overall survival were 23%, 68%, and 79% in the blinatumomab group compared with 49% (P = .001), 42% (P = .001), and 60% (P = .03) in controls. Patients eligible for allogeneic hematopoietic stem cell transplantation (alloHSCT) derived overall benefit. However, no clear additional DFS advantage was observed among those who ultimately underwent transplantation. These findings support the frontline integration of blinatumomab and warrant prospective evaluation of transplantation strategies in this setting. This trial was registered at www.clinicaltrials.gov as #NCT03709719.
引用
- Boissel N, Huguet F, Leguay T, et al. Blinatumomab consolidation for high-risk Ph- B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST study. Blood. 2026. PMID: 42126414. doi:10.1182/blood.2026033309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。